Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 4,272 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Blood samples collected Clear all

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage 0 Hypopharyngeal Carcinoma AJCC v8, Stage 0 Nasopharyngeal Carcinoma AJCC v8, Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Laryngeal Cancer AJCC v8, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage I Nasopharyngeal Carcinoma AJCC v8, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stomatitis
Interventions: Best Practice, Biospecimen Collection, Cisplatin, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, MnSOD Mimetic BMX-001, Placebo Administration, Questionnaire Administration; Other · Procedure · Drug + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 153
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more

Conditions: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer (GC), Colorectal Cancer Screening
Interventions: Not listed
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Insulin Resistance, Diabetes
Interventions: Quantose IR and Quantose IGT analysis, HOMA IR the standard testing for insulin resistance; Diagnostic Test
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Pregnancy
Interventions: Not listed
Lead sponsor: Illumina, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2,209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Phoenix, Arizona • Hagerstown, Maryland • Greensboro, North Carolina + 5 more

Conditions: Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin
Interventions: Pharmacokinetics; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Post-Operative Cancer Patients Experiencing Atrial, Fibrillation
Interventions: questionnaire about the use of ECG device; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 22 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Cutaneous Dysplastic Nevus
Interventions: Biopsy Procedure, Biospecimen Collection, Placebo Administration, Sulforaphane; Procedure · Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Leiomyosarcoma
Interventions: Plasma Collection; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Santa Monica, California • Miami, Florida • Boston, Massachusetts + 6 more

Conditions: Breast Cancer, Invasive Breast Cancer, Carcinoma in Situ of the Breast
Interventions: Tissue Sample collection, Blood Sample Collection, Rectal Swab; Procedure · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Familial Hypercholesterolemia
Interventions: Screening for FH; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Monocytic Leukemia, Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cladribine, Cytarabine, Echocardiography, Lumbar Puncture, Multigated Acquisition Scan, Questionnaire Administration, Venetoclax; Drug · Procedure · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Miami, Florida • Portland, Oregon

Conditions: Amputation Wound, Peripheral Arterial Disease
Interventions: SpectralMD DeepView Wound Imaging System 2.0; Device
Lead sponsor: SpectralMD; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Healthy Volunteer, Cancer
Interventions: 18F-FDG; Drug
Lead sponsor: Akiva Mintz; Other
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Pidnarulex; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypotension
Interventions: Retia Medical Long Time Interval Analysis; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cystic Fibrosis, Polymyxin B
Interventions: Blood Draw; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Gaucher Disease
Interventions: Blood sample; Procedure
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: San Francisco, California • Coral Springs, Florida • Decatur, Georgia + 4 more

Conditions: Anesthesia
Interventions: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%; Drug
Lead sponsor: St. Renatus, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Interventions: filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation; Procedure · Biological · Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 2
States / cities: Indianapolis, Indiana • Boston, Massachusetts

Conditions: Lung Cancer
Interventions: Blood Sample Collection; Other
Lead sponsor: Delfi Diagnostics Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 11,935 participants
Timeline: 2022 – 2026
U.S. locations: 66
States / cities: Cullman, Alabama • Culver City, California • Mission Hills, California + 55 more

Conditions: Type 1 Diabetes
Interventions: FMPD AP algorithm, MPC AP system, Dexcom G6 Continuous Glucose Monitoring (CGM) System; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy Subject, Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Neoplasm
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration; Procedure · Other
Lead sponsor: University of Southern California; Other
Eligibility: 19 Years and older
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Heart Failure, Volume Overload, Decompensated Heart Failure, Systolic Heart Failure
Interventions: Blood Collection, Blood Volume Analysis; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Nodule
Interventions: Blood collection, Chest Computed Tomography; Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Aurora, Colorado • Nashville, Tennessee

Search by objective public record fields.

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

Validation of a Novel Screening Test for Maternal Insulin Resistance

A Study Collecting Blood Samples From Pregnant Women to Aid in the Development of a Noninvasive Prenatal Test

A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant

Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation

Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma

Metastatic Leiomyosarcoma Biomarker Protocol

Prospective Breast Cancer Biospecimen Collection

The ORIGIN-FH Study

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Wound Imaging Study to Gather Clinical References for a Device to Assist Selecting Level-of-amputation in PAD Patients

Ultralow Dose PET Imaging of 18F-FDG Uptake

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

Long Time Interval Analysis for Non Invasive Measurement of Cardiac Output

Pharmacokinetics of Polymyxin B in Adult Patients With Cystic Fibrosis

Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease

Safety and Pharmacokinetics of Kovacaine Nasal Spray (24 Hour Blood Collection)

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

Two Way Crossover Closed Loop Study MPC vs FMPD

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)

A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules